<DOC>
	<DOC>NCT00156949</DOC>
	<brief_summary>Subject incidence of adverse events</brief_summary>
	<brief_title>EPO Deep Tank in Dialysis Subjects</brief_title>
	<detailed_description>To determine whether Epoetin alfa manufactured by a roller bottle technology (Epoetin alfa RB) and Epoetin alfa manufactured by a deep tank process (Epoetin alfa DT) have comparable safety profiles when administered to patients with CKD receiving dialysis.</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>â‰¥ 18 years of age Receiving hemodialysis or peritoneal dialysis Baseline Hb between 11.0 g/dL and 13.0 g/dL Currently receiving Epoetin alfa RB ie. EPOGEN or PROCRIT Transferrin saturation (Tsat) &gt;15.0% Currently receiving or ever received treatment with any erythropoietic stimulating protein other than EPOGEN, Procrit and Aranesp. Uncontrolled hypertension (defined as diastolic blood pressure &gt;110 mmHg or systolic BP &gt;180 mmHg during screening). Grand mal seizure within the last 6 months prior to screening. Acute myocardial ischemia; hospitalization for congestive heart failure or myocardial infarction within 12 weeks before enrollment. Stroke (hemorrhagic or ischemic) or transient ischemic attack within 12 weeks before enrollment. Major surgery within 3 months prior to screening (excluding vascular access surgery). Clinical evidence of systemic infection or inflammatory disease at the time of screening and up until enrollment. For peritoneal dialysis subjects, an episode of peritonitis within 30 days before screening. Known positivity for HIV antibody or Hepatitis B surface antigen. Clinical evidence of current malignancy with the exception of basal cell or squamous cell carcinoma of the skin. Blood transfusions within 8 weeks prior to screening or active bleeding. Androgen therapy within 8 weeks prior to screening. Systemic hematological disease (eg ,sickle cell anemia, myelodysplastic syndromes, hematological malignancy); myeloma; hemolytic anemia. Other investigational products are excluded. Subject is currently enrolled in, or has not yet completed, a period of at least 30 days since ending other investigational device or drug trial(s). Psychiatric, addictive, or any other disorder that compromises ability to give truly informed consent for participation in this study. Pregnant or breast feeding (women of childbearing potential must be taking adequate contraceptive precautions). Anticipating or scheduled for a livingrelated kidney transplant. Known history of severe hyperparathyroidism (PTH &gt;1500pg/ml) within 3 months prior top enrollment. Currently receiving home hemodialysis treatment. Currently receiving immunosuppressive therapy.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Epogen</keyword>
	<keyword>Procrit</keyword>
	<keyword>Chronic Kidney Disease</keyword>
	<keyword>Anemia Treatment for Dialysis Patients</keyword>
</DOC>